Elaine Caughey - 21 Jun 2021 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role
Chief Business Officer
Signature
/s/ Bruce Jacobs, as Attorney-in-Fact
Issuer symbol
KYMR
Transactions as of
21 Jun 2021
Net transactions value
$0
Form type
4
Filing time
21 Jun 2021, 17:36:39 UTC
Next filing
03 Mar 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Award $0 +100,000 $0.000000 100,000 21 Jun 2021 Common Stock 100,000 $47.56 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the shares underlying this stock option shall vest on June 21, 2022, and the remainder shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.